A Message to Nanobac Pharmaceuticals Shareholders.

TAMPA, Fla. -- Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced last year a sharpened focus in three areas: 1) developing safe and effective drug therapies for diseases where soft tissue calcification, or "calcium deposits," is a dominant feature, 2) validating the Company's antibody and antigen derived diagnostics to determine levels of calcification, and 3) scientific studies to determine the infectious nature of the calcifying nano particles (CNPs).

The sharpened focus on drug therapies led to a Pre-IND (Investigational New Drug) meeting with the FDA on January 19, 2007. With positive results from this meeting, the Company is moving forward with the IND application for Chronic prostatitis/Chronic pelvic pain syndrome (CP/CPPS) also referred to as category III prostatitis. In the United States, more than 2 million men per year visit their physician for prostatitis. Nanobac's strategic partner at the Cleveland Clinic will be the principal investigator for the clinical trial portion of this IND.

The sharpened focus on diagnostics has uncovered interesting characteristics about the nature of CNPs and their interaction with certain rogue proteins. Nanobac's Finnish science team is coordinating the efforts on validating these new findings with strategic partners in Canada and at the Johnson Space Center in Houston.

The sharpened focus on determining if there is an infectious nature to CNPs is through collaborative efforts with the Mayo Clinic and investigators at China's Coal Medical College. These studies are scheduled to conclude in June. If successful, we will establish that CNPs are a causative agent in the formation of calcific diseases, and in the specific case of the China study, Gall Stones. It also suggests that CNPs might play a similar role in the formation of kidney stones, prostatic stones and could be the agent involved with the calcification stage of atherosclerosis.

"The Company will continue optimizing its proprietary diagnostics, with a clear focus on developing effective therapies in cooperation with well-established partners including NASA, Mayo Clinic, Cleveland Clinic, and potential new partners in the pharmaceutical industry. Once these experiments are completed, we hope to have a compelling and well-rounded scientific basis for the Company to move forward," Dr. Benedict Maniscalco, Co-Chair and Chief Medical Officer stated.

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals, Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.